Want to see AU:BIT full AI Analyst Report?
Top Page
Biotron
(Sydney:BIT)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.01
▲(450.00% Upside)
Action:Reiterated
Date:08/04/26
The score is primarily driven by financial performance: despite improved FY2025 losses and minimal debt, AU:BIT remains loss-making with consistently negative operating and free cash flow and volatile, small revenue. Valuation is also constrained by the negative P/E and lack of dividend yield, while technical analysis is neutral due to missing indicator data.
Positive Factors
Low leverage / No debt
A near-zero debt position materially reduces financial risk and interest burden over the medium term. This gives management flexibility to fund R&D via equity or partnerships rather than servicing debt, lowers insolvency risk during clinical trials, and preserves operational runway.
Negative Factors
Negative operating & free cash flow
Persistent negative operating and free cash flow indicate ongoing reliance on external financing to sustain operations. Over a multi-month horizon this raises dilution risk, constrains strategic flexibility, and may force prioritization or delay of development programs if fresh capital is limited.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / No debt
A near-zero debt position materially reduces financial risk and interest burden over the medium term. This gives management flexibility to fund R&D via equity or partnerships rather than servicing debt, lowers insolvency risk during clinical trials, and preserves operational runway.
Read all positive factors
Biotron (BIT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.57M
Dividend YieldN/A
Average Volume (3M)1.60M
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS Growth-21.43%
CountryAU
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,785,205,000
10 Day Avg. Volume3,265,462
30 Day Avg. Volume1,601,469
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.63
Price to Sales (P/S)1.10
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biotron Business Overview & Revenue Model
Company Description
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase...
How the Company Makes Money
null...
Biotron Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -868.00 | 1.81M | 1.65M | 1.43M | 1.56M | 1.46M |
| Gross Profit | -1.65K | 1.81M | 1.65M | 1.39M | 1.51M | 1.41M |
| EBITDA | -1.92M | -333.81K | -5.04M | -4.88M | -2.73M | -4.56M |
| Net Income | -1.94M | -318.57K | -3.44M | -3.49M | -2.78M | -3.19M |
Balance Sheet | ||||||
| Total Assets | 3.86M | 980.40K | 493.48K | 4.14M | 1.91M | 4.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1.64M | 931.68K | 393.20K | 3.98M | 1.74M | 4.21M |
| Total Debt | 0.00 | 0.00 | 7.13K | 45.27K | 77.24K | 6.35K |
| Total Liabilities | 1.16M | 428.51K | 737.51K | 962.49K | 813.57K | 463.51K |
| Stockholders Equity | 2.70M | 551.89K | -244.03K | 3.17M | 1.09M | 3.86M |
Cash Flow | ||||||
| Free Cash Flow | -1.92M | -568.87K | -3.57M | -3.29M | -2.44M | -3.41M |
| Operating Cash Flow | -1.92M | -565.80K | -3.57M | -3.29M | -2.44M | -3.41M |
| Investing Cash Flow | 111.51K | -3.07K | 0.00 | 0.00 | 0.00 | -5.72K |
| Financing Cash Flow | 2.58M | 1.11M | -22.62K | 5.53M | -33.17K | -36.96K |
Biotron Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$63.84M | 65.12 | 17.85% | ― | 38.44% | 230.77% | |
52 Neutral | AU$11.62M | -1.93 | -43.95% | ― | 14.30% | 41.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$357.79M | -97.40 | -15.96% | ― | 364.97% | 74.58% | |
46 Neutral | AU$5.57M | -6.67 | -119.12% | ― | ― | -21.43% | |
43 Neutral | AU$8.88M | -3.24 | -140.35% | ― | ― | ― | |
41 Neutral | AU$113.04M | -3.27 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:BIT
Biotron
―
―
―
AU:SPL
Starpharma Holdings Limited
0.80
0.70
684.31%
AU:IMC
Immuron Limited
0.03
-0.03
-51.52%
AU:BGT
Bio-Gene Technology Ltd.
0.02
<0.01
4.55%
AU:BIO
Biome Australia Ltd
0.29
-0.24
-45.71%
AU:RCE
Recce Pharmaceuticals Ltd.
0.38
0.00
0.00%
Biotron Corporate Events
Biotron Updates Market on Directors’ Shareholding Changes
Jul 15, 2026
Biotron Limited has notified the ASX of changes in the shareholdings of directors Paul Kasian and Graeme Wald, in accordance with listing rule 3.19A. The disclosure reinforces the company’s commitment to regulatory compliance and transparent...
Biotron Seeks ASX Quotation for 83 Million New Shares
Jul 13, 2026
Biotron Limited has applied for quotation on the ASX of 83,333,333 new ordinary fully paid shares, expanding its listed securities base under the ticker BIT. The newly issued shares, dated 13 July 2026, arise from the exercise or conversion of exi...
Biotron Clears First SedRx Milestone After EMA Feedback on Regulatory Pathway
Jul 13, 2026
Biotron has met the first milestone under its Sedarex acquisition after securing formal feedback from the European Medicines Agency on the regulatory pathway for SedRx. The EMA guidance gives the company a clearer roadmap for designing pivotal cli...
Biotron Lists Additional Ordinary Shares Following Option Conversions
Jun 17, 2026
Biotron Limited has applied for quotation on the ASX of 5,720 new ordinary fully paid shares, to be listed under its existing ticker BIT. The securities arise from the exercise or conversion of existing options or other convertible instruments, re...
Biotron Secures R&D Tax Rebate to Support Antiviral Drug Development
Jun 3, 2026
Biotron Limited has received an RD Tax Incentive rebate of $525,869 from the Australian Government for the 2024/25 financial year, reflecting 43.5% of its eligible research and development expenditure. The rebate, derived from its antiviral drug d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.